APA (7th ed.) Citation

Mayer, K. A., Schrezenmeier, E., Diebold, M., Halloran, P. F., Schatzl, M., Schranz, S., . . . Vietzen, H. (2024). A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. New England Journal of Medicine, 391(2), 122. https://doi.org/10.1056/NEJMoa2400763

Chicago Style (17th ed.) Citation

Mayer, K. A., et al. "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection." New England Journal of Medicine 391, no. 2 (2024): 122. https://doi.org/10.1056/NEJMoa2400763.

MLA (9th ed.) Citation

Mayer, K. A., et al. "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection." New England Journal of Medicine, vol. 391, no. 2, 2024, p. 122, https://doi.org/10.1056/NEJMoa2400763.